- CIIX’s goal is 100% growth, cost cuts and profitability in FY2018 after recording 76% YOY operating sales jump in FY2017
- Valuation of CIIX “could explode with this huge potential market in China of 1.4 billion people,” according to investor relations director in SmallCapVoice interview
- Consilium Global Research projects CIIX sales will reach $14.8 million by FY2020
ChineseInvestors.com, Inc. (OTCQB: CIIX) is growing in numerous directions due to its diverse strategy of marketing, communications and product development both within China and to the global Chinese-speaking community. After recording YOY operating sales gains of 130% in investor relations and 57% in subscription revenue in FY2017, CEO Warren Wang said that the company’s goal is 100% more growth in FY2018 while cutting costs and achieving profitability. Overall, the company showed 76% YOY operating sales growth in FY2017. Diversity is the key to this skyrocketing growth (http://cnw.fm/Kl9Ud).
Through its subsidiary, CBD Biotechnology Co. Ltd., CIIX is marketing, to the 1.4 billion people of China, its CBD-infused skin care line through multiple-channels, including retail, social media and direct marketing, Alan Klitenic, director of investor relations for CIIX, told SmallCapVoice.com in an interview (http://cnw.fm/J5OHp).
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer